Which therapy works best for kids with MIS-C?
NCT ID NCT04898231
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 73 children with MIS-C, a rare inflammatory condition linked to COVID-19. Researchers compared three treatments—infliximab, anakinra, and steroids—to see which helped kids recover fastest without needing more therapy. The goal was to find the safest and most effective option for managing this serious illness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
73 people
The number who actually took part.
- Started
-
Dec 2020
- Finished
-
Apr 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Up to 20 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. An individual aged \<21 years presenting with 1. Fever (\>38.0°C for ≥24 hours; may be by subjective report) AND 2. Two or more of the following (from two different systems; e.g. one from cardiac and one from mucocutaneous): Cardiac * Hypotension * Shock * Arrhythmia * Tachycardia * Left ventricular ejection fraction \<55% * Valvulitis * Coronary artery enlargement (LAD or RCA Z-score ≥ 2.5) * Pericardial effusion Gastrointestinal * Diarrhea * Nausea/vomiting * Significant abdominal pain Immunologic * Lymphadenopathy (unilateral cervical or diffuse) Mucocutaneous * Bilateral conjunctival injection * Extremity swelling or erythema * Rash * Lip erythema/Strawberry tongue Neurologic * Altered mental status * Focal neurological deficits * Headache * Meningismus 3. Laboratory evidence of inflammation, including but not limited to, an elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, D-dimer, ferritin, lactic acid dehydrogenase (LDH), neutrophilia, lymphopenia or hypoalbuminemia AND 4. No alternative plausible diagnoses based on clinical judgement AND 5. Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or suspected COVID-19 exposure AND 6. Parent or legal guardian (or self if at least 18 years old) able and willing to provide informed consent and subject willing and able to provide assent when appropriate. Exclusion Criteria: 1. Known immunodeficiency 2. Pre-existing medical condition that precludes receiving one or more of the study medications (e.g. TB, drug allergy to study medication).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Multisystem inflammatory syndrome-children are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital Michigan
Detroit, Michigan, 48201, United States
-
Rady Children's Hospital
San Diego, California, 92123, United States